Attention deficit hyperactivity disorder (ADHD) used to be considered a mild childhood condition that manifested mostly in the school setting and remitted by adolescence. More recently, a large body of evidence has shown that it is a very frequent psychiatric problem in childhood, causes considerable suffering in patients and their families, and persists in adulthood 70% of the time. This chapter outlines current pharmacological treatment options available to office based clinicians who wish to provide treatment for ADHD. Each FDA approved agent is reviewed in detail focusing on the safety profile and efficacy data, as well as the monitoring tools that can be utilized to optimize treatment. This review also addresses recent controversies in the field and provides practical clinical advice within a Frequently Asked Question format.
|Title of host publication||Clinical Aspects of Psychopharmacology in Childhood and Adolescence|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||27|
|State||Published - 1 Jan 2011|